May 19 Quick Takes: Be Biopharma, National Resilience partner

Be Biopharma Inc. partnered with National Resilience Inc. in a deal that applies Resilience’s new modality manufacturing capabilities to Be Bio’s B cell therapy platform — a modality for which manufacturing processes are still largely unestablished. The companies entered a risk-sharing and cost-sharing agreement in which Resilience is eligible for milestones and royalties. In exchange, Resilience will provide GMP-grade viral vector and cell therapy drug product manufacturing for Be Bio’s initial rare disease pipeline programs.

Cambrian Biopharma provided newly launched subsidiary Oviva Therapeutics Inc. with $11.5 million in seed funding to develop a program in-licensed from Massachusetts General Hospital addressing ovarian aging. The start-up is the second launched under the umbrella of Cambrian, which is seeking to develop aging disease-related assets through a hub-and-spoke model. Cambrian also backed mTOR inhibitor developer Tornado Therapeutics in February...